Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model.


Journal

Nature genetics
ISSN: 1546-1718
Titre abrégé: Nat Genet
Pays: United States
ID NLM: 9216904

Informations de publication

Date de publication:
02 2020
Historique:
received: 01 07 2019
accepted: 18 12 2019
pubmed: 7 2 2020
medline: 14 4 2020
entrez: 7 2 2020
Statut: ppublish

Résumé

Somatic alterations in cancer genes are being detected in normal and premalignant tissue, thus placing greater emphasis on gene-environment interactions that enable disease phenotypes. By combining early genetic alterations with disease-relevant exposures, we developed an integrative mouse model to study gastric premalignancy. Deletion of Trp53 in gastric cells confers a selective advantage and promotes the development of dysplasia in the setting of dietary carcinogens. Organoid derivation from dysplastic lesions facilitated genomic, transcriptional and functional evaluation of gastric premalignancy. Cell cycle regulators, most notably Cdkn2a, were upregulated by p53 inactivation in gastric premalignancy, serving as a barrier to disease progression. Co-deletion of Cdkn2a and Trp53 in dysplastic gastric organoids promoted cancer phenotypes but also induced replication stress, exposing a susceptibility to DNA damage response inhibitors. These findings demonstrate the utility of mouse models that integrate genomic alterations with relevant exposures and highlight the importance of gene-environment interactions in shaping the premalignant state.

Identifiants

pubmed: 32025000
doi: 10.1038/s41588-019-0574-9
pii: 10.1038/s41588-019-0574-9
pmc: PMC7031028
mid: NIHMS1546989
doi:

Substances chimiques

Cdkn2a protein, mouse 0
Cyclin-Dependent Kinase Inhibitor p16 0
TP53 protein, human 0
Trp53 protein, mouse 0
Tumor Suppressor Protein p53 0
Methylnitrosourea 684-93-5

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

219-230

Subventions

Organisme : NIDDK NIH HHS
ID : K08 DK120930
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA163059
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK034854
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA127003
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006516
Pays : United States
Organisme : NIDDK NIH HHS
ID : K08 DK109209
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA098101
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Wagner, A. D. et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 8, CD004064 (2017).
pubmed: 28850174
Yang, K. et al. Dietary modulation of carcinoma development in a mouse model for human familial adenomatous polyposis. Cancer Res. 58, 5713–5717 (1998).
pubmed: 9865728
Polak, P. et al. Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature 518, 360–364 (2015).
pubmed: 25693567 pmcid: 4405175 doi: 10.1038/nature14221
The Cancer Genome Atlas Research Network Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–175 (2017).
pmcid: 5651175 doi: 10.1038/nature20805
Quante, M. et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 21, 36–51 (2012).
pubmed: 22264787 pmcid: 3266546 doi: 10.1016/j.ccr.2011.12.004
Giroux, V. & Rustgi, A. K. Metaplasia: tissue injury adaptation and a precursor to the dysplasia-cancer sequence. Nat. Rev. Cancer 17, 594–604 (2017).
pubmed: 28860646 pmcid: 5998678 doi: 10.1038/nrc.2017.68
Chen, S. L., Mo, J. Z., Cao, Z. J., Chen, X. Y. & Xiao, S. D. Effects of bile reflux on gastric mucosal lesions in patients with dyspepsia or chronic gastritis. World J. Gastroenterol. 11, 2834–2837 (2005).
pubmed: 15884134 pmcid: 4305928 doi: 10.3748/wjg.v11.i18.2834
Sobala, G. M. et al. Bile reflux and intestinal metaplasia in gastric mucosa. J. Clin. Pathol. 46, 235–240 (1993).
pubmed: 8463417 pmcid: 501177 doi: 10.1136/jcp.46.3.235
Stefaniwsky, A. B., Tint, G. S., Speck, J., Shefer, S. & Salen, G. Ursodeoxycholic acid treatment of bile reflux gastritis. Gastroenterology 89, 1000–1004 (1985).
pubmed: 4043659 doi: 10.1016/0016-5085(85)90200-8
Tomita, H. et al. Inhibition of gastric carcinogenesis by the hormone gastrin is mediated by suppression of TFF1 epigenetic silencing. Gastroenterology 140, 879–891 (2011).
pubmed: 21111741 doi: 10.1053/j.gastro.2010.11.037
Lijinsky, W. & Epstein, S. S. Nitrosamines as environmental carcinogens. Nature 225, 21–23 (1970).
pubmed: 5409687 doi: 10.1038/225021a0
Lijinsky, W. N-Nitroso compounds in the diet. Mutat. Res. 443, 129–138 (1999).
pubmed: 10415436 doi: 10.1016/S1383-5742(99)00015-0
Ding, L., El Zaatari, M. & Merchant, J. L. Recapitulating human gastric cancer pathogenesis: experimental models of gastric cancer. Adv. Exp. Med. Biol. 908, 441–478 (2016).
pubmed: 27573785 pmcid: 5499694 doi: 10.1007/978-3-319-41388-4_22
Petersen, C. P., Mills, J. C. & Goldenring, J. R. Murine models of gastric corpus preneoplasia. Cell Mol. Gastroenterol. Hepatol. 3, 11–26 (2017).
pubmed: 28174755 doi: 10.1016/j.jcmgh.2016.11.001
Yamachika, T. et al. N-methyl-N-nitrosourea concentration-dependent, rather than total intake-dependent, induction of adenocarcinomas in the glandular stomach of BALB/c mice. Jpn J. Cancer Res. 89, 385–391 (1998).
pubmed: 9617343 pmcid: 5921815 doi: 10.1111/j.1349-7006.1998.tb00575.x
Fox, J. G. et al. Germ-line p53-targeted disruption inhibits Helicobacter-induced premalignant lesions and invasive gastric carcinoma through down-regulation of Th1 proinflammatory responses. Cancer Res. 62, 696–702 (2002).
pubmed: 11830522
Wang, T. C. et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 118, 36–47 (2000).
pubmed: 10611152 doi: 10.1016/S0016-5085(00)70412-4
Wang, T. C. et al. Mice lacking secretory phospholipase A2 show altered apoptosis and differentiation with Helicobacter felis infection. Gastroenterology 114, 675–689 (1998).
pubmed: 9516388 doi: 10.1016/S0016-5085(98)70581-5
Hayakawa, Y. et al. Mist1 expressing gastric stem cells maintain the normal and neoplastic gastric epithelium and are supported by a perivascular stem cell niche. Cancer Cell 28, 800–814 (2015).
pubmed: 26585400 pmcid: 4684751 doi: 10.1016/j.ccell.2015.10.003
Hayakawa, Y., Fox, J. G. & Wang, T. C. The origins of gastric cancer from gastric stem cells: lessons from mouse models. Cell. Mol. Gastroenterol. Hepatol. 3, 331–338 (2017).
pubmed: 28462375 pmcid: 5404024 doi: 10.1016/j.jcmgh.2017.01.013
Sarkar, A. et al. Sox2 suppresses gastric tumorigenesis in mice. Cell Rep. 16, 1929–1941 (2016).
pubmed: 27498859 doi: 10.1016/j.celrep.2016.07.034
Leushacke, M. et al. Lgr5-expressing chief cells drive epithelial regeneration and cancer in the oxyntic stomach. Nat. Cell Biol. 19, 774–786 (2017).
pubmed: 28581476 doi: 10.1038/ncb3541
Dulak, A. M. et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 45, 478–486 (2013).
pubmed: 23525077 pmcid: 3678719 doi: 10.1038/ng.2591
Stachler, M. D. et al. Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat. Genet. 47, 1047–1055 (2015).
pubmed: 26192918 pmcid: 4552571 doi: 10.1038/ng.3343
Zang, Z. J. et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 44, 570–574 (2012).
pubmed: 22484628 doi: 10.1038/ng.2246
Sperling, A. S., Gibson, C. J. & Ebert, B. L. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat. Rev. Cancer 17, 5–19 (2017).
pubmed: 27834397 doi: 10.1038/nrc.2016.112
Steensma, D. P. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126, 9–16 (2015).
pubmed: 25931582 pmcid: 4624443 doi: 10.1182/blood-2015-03-631747
Huang, K. K. et al. Genomic and epigenomic profiling of high-risk intestinal metaplasia reveals molecular determinants of progression to gastric cancer. Cancer Cell 33, 137–150.e5 (2018).
pubmed: 29290541 doi: 10.1016/j.ccell.2017.11.018
Maley, C. C. et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38, 468–473 (2006).
pubmed: 16565718 doi: 10.1038/ng1768
Shimizu, T. et al. Accumulation of somatic mutations in TP53 in gastric epithelium with Helicobacter pylori infection. Gastroenterology 147, 407–17 e3 (2014).
pubmed: 24786892 doi: 10.1053/j.gastro.2014.04.036
Stachler, M. D. et al. Detection of mutations in Barrett's esophagus before progression to high-grade dysplasia or adenocarcinoma. Gastroenterology 155, 156–167 (2018).
pubmed: 29608884 doi: 10.1053/j.gastro.2018.03.047
Wang, L., Guo, H., Lin, C., Yang, L. & Wang, X. Enrichment and characterization of cancer stemlike cells from a cervical cancer cell line. Mol. Med. Rep. 9, 2117–2123 (2014).
pubmed: 24676900 pmcid: 4055449 doi: 10.3892/mmr.2014.2063
Van de Peer, Y., Mizrachi, E. & Marchal, K. The evolutionary significance of polyploidy. Nat. Rev. Genet. 18, 411–424 (2017).
pubmed: 28502977 doi: 10.1038/nrg.2017.26
Mirvish, S. S. Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. Cancer Lett. 93, 17–48 (1995).
pubmed: 7600541 doi: 10.1016/0304-3835(95)03786-V
Bulay, O. et al. Carcinogenicity test of six nitrosamides and a nitrosocyanamide administered orally to rats. J. Natl. Cancer Inst. 62, 1523–1528 (1979).
pubmed: 286123
Tu, S. et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14, 408–419 (2008).
pubmed: 18977329 pmcid: 2586894 doi: 10.1016/j.ccr.2008.10.011
Westcott, P. M. et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517, 489–492 (2015).
pubmed: 25363767 doi: 10.1038/nature13898
Barker, N. et al. Lgr5
pubmed: 20085740 doi: 10.1016/j.stem.2009.11.013
Goldenring, J. R., Nam, K. T. & Mills, J. C. The origin of pre-neoplastic metaplasia in the stomach: chief cells emerge from the Mist. Exp. Cell Res. 317, 2759–2764 (2011).
pubmed: 21907708 pmcid: 3210373 doi: 10.1016/j.yexcr.2011.08.017
Bielski, C. M. et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat. Genet. 50, 1189–1195 (2018).
pubmed: 30013179 pmcid: 6072608 doi: 10.1038/s41588-018-0165-1
Taylor, A. M. et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell 33, 676–689 e3 (2018).
pubmed: 29622463 pmcid: 6028190 doi: 10.1016/j.ccell.2018.03.007
The Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).
doi: 10.1038/nature13480
Liu, Y. et al. Comparative molecular analysis of gastrointestinal adenocarcinomas. Cancer Cell 33, 721–735.e8 (2018).
pubmed: 29622466 pmcid: 5966039
Galipeau, P. C. et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc. Natl Acad. Sci. USA 93, 7081–7084 (1996).
pubmed: 8692948 pmcid: 38939 doi: 10.1073/pnas.93.14.7081
Galipeau, P. C., Prevo, L. J., Sanchez, C. A., Longton, G. M. & Reid, B. J. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett’s) tissue. J. Natl. Cancer Inst. 91, 2087–2095 (1999).
pubmed: 10601379 doi: 10.1093/jnci/91.24.2087
Nanki, K. et al. Divergent routes toward Wnt and R-spondin niche independency during human gastric carcinogenesis. Cell 174, 856–869.e17 (2018).
pubmed: 30096312 doi: 10.1016/j.cell.2018.07.027
Ross-Innes, C. S. et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nat. Genet. 47, 1038–1046 (2015).
pubmed: 26192915 pmcid: 4556068 doi: 10.1038/ng.3357
Jaenisch, R. & Young, R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 132, 567–582 (2008).
pubmed: 18295576 pmcid: 4142810 doi: 10.1016/j.cell.2008.01.015
Yaeger, R. et al. Genomic alterations observed in colitis-associated cancers are distinct from those found in sporadic colorectal cancers and vary by type of inflammatory bowel disease. Gastroenterology 151, 278–287 e6 (2016).
pubmed: 27063727 doi: 10.1053/j.gastro.2016.04.001
Sharpless, N. E. & DePinho, R. A. The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 9, 22–30 (1999).
pubmed: 10072356 doi: 10.1016/S0959-437X(99)80004-5
Chin, L. et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev. 11, 2822–2834 (1997).
pubmed: 9353252 pmcid: 316663 doi: 10.1101/gad.11.21.2822
Kamijo, T. et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl Acad. Sci. USA 95, 8292–8297 (1998).
pubmed: 9653180 pmcid: 20969 doi: 10.1073/pnas.95.14.8292
Pomerantz, J. et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92, 713–723 (1998).
pubmed: 9529248 doi: 10.1016/S0092-8674(00)81400-2
Stott, F. J. et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17, 5001–5014 (1998).
pubmed: 9724636 pmcid: 1170828 doi: 10.1093/emboj/17.17.5001
Zhang, Y., Xiong, Y. & Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725–734 (1998).
pubmed: 9529249 doi: 10.1016/S0092-8674(00)81401-4
Lukas, J. et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375, 503–506 (1995).
pubmed: 7777060 doi: 10.1038/375503a0
Otterson, G. A., Kratzke, R. A., Coxon, A., Kim, Y. W. & Kaye, F. J. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 9, 3375–3378 (1994).
pubmed: 7936665
Russo, A. A., Tong, L., Lee, J. O., Jeffrey, P. D. & Pavletich, N. P. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395, 237–243 (1998).
pubmed: 9751050 doi: 10.1038/26155
Shapiro, G. I. et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res. 55, 505–509 (1995).
pubmed: 7834618
Tanaka, H. et al. Disruption of the RB pathway and cell-proliferative activity in non-small-cell lung cancers. Int. J. Cancer 79, 111–115 (1998).
pubmed: 9583722 doi: 10.1002/(SICI)1097-0215(19980417)79:2<111::AID-IJC2>3.0.CO;2-W
Maley, C. C. et al. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res. 64, 7629–7633 (2004).
pubmed: 15492292 doi: 10.1158/0008-5472.CAN-04-1738
Maley, C. C. et al. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res. 64, 3414–3427 (2004).
pubmed: 15150093 doi: 10.1158/0008-5472.CAN-03-3249
Buas, M. F. et al. Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. Carcinogenesis 35, 2740–2747 (2014).
pubmed: 25280564 pmcid: 4247522 doi: 10.1093/carcin/bgu207
Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78–83 (2017).
pubmed: 28059767 pmcid: 5367887 doi: 10.1126/science.aah4199
Mu, P. et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355, 84–88 (2017).
pubmed: 28059768 pmcid: 5247742 doi: 10.1126/science.aah4307
Shapiro, G. I., Edwards, C. D., Ewen, M. E. & Rollins, B. J. p16INK4A participates in a G1 arrest checkpoint in response to DNA damage. Mol. Cell Biol. 18, 378–387 (1998).
pubmed: 9418885 pmcid: 121508 doi: 10.1128/MCB.18.1.378
Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864–870 (2005).
pubmed: 15829956 doi: 10.1038/nature03482
Gorgoulis, V. G. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907–913 (2005).
pubmed: 15829965 doi: 10.1038/nature03485
Chen, Z. et al. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int. J. Cancer 119, 2784–2794 (2006).
pubmed: 17019715 doi: 10.1002/ijc.22198
Reaper, P. M. et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 7, 428–430 (2011).
pubmed: 21490603 doi: 10.1038/nchembio.573
Gadhikar, M. A. et al. CDKN2A/p16 deletion in head and neck cancer cells is associated with CDK2 activation, replication stress, and vulnerability to CHK1 inhibition. Cancer Res. 78, 781–797 (2018).
pubmed: 29229598 doi: 10.1158/0008-5472.CAN-17-2802
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
pubmed: 22588877 doi: 10.1158/2159-8290.CD-12-0095
Lv, L. et al. Tetraploid cells from cytokinesis failure induce aneuploidy and spontaneous transformation of mouse ovarian surface epithelial cells. Cell Cycle 11, 2864–2875 (2012).
pubmed: 22801546 pmcid: 3419060 doi: 10.4161/cc.21196
Shi, G. et al. Loss of the acinar-restricted transcription factor Mist1 accelerates Kras-induced pancreatic intraepithelial neoplasia. Gastroenterology 136, 1368–1378 (2009).
pubmed: 19249398 doi: 10.1053/j.gastro.2008.12.066
Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84–87 (2014).
pubmed: 24336571 doi: 10.1126/science.1247005
Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784 (2014).
pubmed: 25075903 pmcid: 4486245 doi: 10.1038/nmeth.3047
Wong, G. S. et al. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat. Med. 24, 968–977 (2018).
pubmed: 29808010 pmcid: 6039276 doi: 10.1038/s41591-018-0022-x
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
pubmed: 19451168 pmcid: 2705234 doi: 10.1093/bioinformatics/btp324
McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
pubmed: 20644199 pmcid: 2928508 doi: 10.1101/gr.107524.110
Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).
pubmed: 23396013 pmcid: 3833702 doi: 10.1038/nbt.2514
Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
pubmed: 20601685 pmcid: 2938201 doi: 10.1093/nar/gkq603
Kim, J. et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat. Genet. 48, 600–606 (2016).
pubmed: 27111033 pmcid: 4936490 doi: 10.1038/ng.3557
Boeva, V. et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics 28, 423–425 (2012).
pubmed: 22155870 doi: 10.1093/bioinformatics/btr670
Scheinin, I. et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res. 24, 2022–2032 (2014).
pubmed: 25236618 pmcid: 4248318 doi: 10.1101/gr.175141.114
Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).
pubmed: 20196867 pmcid: 2864565 doi: 10.1186/gb-2010-11-3-r25
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
pubmed: 19910308 doi: 10.1093/bioinformatics/btp616
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
pubmed: 25605792 pmcid: 4402510 doi: 10.1093/nar/gkv007
Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).
pubmed: 24485249 pmcid: 4053721 doi: 10.1186/gb-2014-15-2-r29
Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N. & Golani, I. Controlling the false discovery rate in behavior genetics research. Behav. Brain Res. 125, 279–284 (2001).
pubmed: 11682119 doi: 10.1016/S0166-4328(01)00297-2
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 16199517 pmcid: 1239896 doi: 10.1073/pnas.0506580102
Sergushichev, A. A. et al. GAM: a web-service for integrated transcriptional and metabolic network analysis. Nucleic Acids Res. 44, W194–W200 (2016).
pubmed: 27098040 pmcid: 4987878 doi: 10.1093/nar/gkw266
Liberzon, A. et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
pubmed: 26771021 pmcid: 4707969 doi: 10.1016/j.cels.2015.12.004
Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
pubmed: 22460905 pmcid: 3320027 doi: 10.1038/nature11003
Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108–112 (2009).
pubmed: 19847166 pmcid: 2783335 doi: 10.1038/nature08460
Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).
pubmed: 23323831 pmcid: 3618321 doi: 10.1186/1471-2105-14-7
Seashore-Ludlow, B. et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov. 5, 1210–1223 (2015).
pubmed: 26482930 pmcid: 4631646 doi: 10.1158/2159-8290.CD-15-0235
Cowley, G. S. et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci. Data 1, 140035 (2014).
pubmed: 25984343 pmcid: 4432652 doi: 10.1038/sdata.2014.35

Auteurs

Nilay S Sethi (NS)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. nilay_sethi@dfci.harvard.edu.
Gastrointestinal Cancer Treatment Center, Dana-Farber Cancer Institute, Boston, MA, USA. nilay_sethi@dfci.harvard.edu.
Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. nilay_sethi@dfci.harvard.edu.

Osamu Kikuchi (O)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Gina N Duronio (GN)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Matthew D Stachler (MD)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.

James M McFarland (JM)

Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.

Ruben Ferrer-Luna (R)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.

Yanxi Zhang (Y)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Chunyang Bao (C)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Roderick Bronson (R)

Department of Pathology, Harvard Medical School, Boston, MA, USA.

Deepa Patil (D)

Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

Francisco Sanchez-Vega (F)

Department of Surgery and Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Jie-Bin Liu (JB)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Ewa Sicinska (E)

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.

Jean-Bernard Lazaro (JB)

Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Keith L Ligon (KL)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.

Rameen Beroukhim (R)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.

Adam J Bass (AJ)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. adam_bass@dfci.harvard.edu.
Gastrointestinal Cancer Treatment Center, Dana-Farber Cancer Institute, Boston, MA, USA. adam_bass@dfci.harvard.edu.
Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. adam_bass@dfci.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH